摘要
免疫检查点抑制剂作为新兴的肿瘤治疗方法,因其良好的疗效而受到广泛的关注。大量研究表明针对细胞毒性T淋巴细胞相关抗原(cytotoxic T lymphocyte-associated protein-4,CTLA-4)和程序性死亡受体-1(programmed death-1,PD-1)/程序性死亡配体-1(programmed death ligand-1,PD-L1)的免疫检查点抑制剂对实体肿瘤具有免疫调控的作用,从而表现出抗肿瘤作用。随着各类免疫检查点抑制剂的上市,对免疫检查点疗法的机制以及免疫治疗相关不良反应(immune-related adverse events,ir AEs)的研究也更加深入。本文就免疫检查点抑制剂作用机制、临床前毒性反应及ir AEs的研究进展作一综述,以归纳总结其不良反应,为其临床前安全性评价、临床试验的设计提供参考。
As a new method of tumor therapy,immune checkpoint inhibitors are paid close attention to because of their good curative effects.A large number of studies have shown that the immune checkpoint inhibitors targeted at cytotoxic T lymphocyte-associated protein-4(CTLA-4)and programmed death-1/programmed death ligand-1(PD-1/PD-L1)have immunoregulatory effects on solid tumors,thus showing anti-tumor effect.With the approvals of various kinds of immune checkpoint inhibitors,the mechanism of immune checkpoint therapy and immune-related adverse events(ir AEs)are further studied.In this paper,the studies on the mechanism of action,preclinical toxicity and ir AEs of immune checkpoint inhibitors were reviewed to preliminarily summarize their adverse reactions and provided reference for non-clinical safety evaluation and design of clinical studies.
作者
钱仪敏
李华
马璟
QIAN Yi-min;LI Hua;MA Jing(China State Institute of Pharmaceutical Industry National Shanghai Center for New Drug Safety Evaluation&Research,Shanghai InnoStar Biotech Co.,Ltd.,Shanghai 201203,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2019年第8期921-925,共5页
Chinese Journal of New Drugs
基金
国家"重大新药创制"科技重大专项资助项目(2018ZX09201017-008)
上海市研发公共服务平台项目(18DZ2290100)
